Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
December 11, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates,...
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
December 04, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Preclinical data show magnesium-potentiation...
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
November 28, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates,...
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia
November 15, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline results expected late December 2023 RESILIENT is expected to be the final efficacy trial required for submission of a New Drug Application to FDA; first successful Phase 3 trial,...
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
November 13, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Children with Autism Spectrum Disorder are at Risk for Low Bone Density Preliminary Data Suggest that the Administration of Oxytocin May Favorably Impact Bone Formation and Strength Recent...
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
November 09, 2023 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline Results from Phase 3 Potentially NDA-Enabling Study of TNX-102 SL in Fibromyalgia Expected Late December 2023: Centrally-Acting Non-Opioid Analgesic Topline Results from Phase 2...
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
November 02, 2023 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NIAID is conducting early phase clinical trials on select next generation COVID-19 vaccine candidates with the intent to identify promising vaccine candidates TNX-1800, a live virus percutaneous...
Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder
October 31, 2023 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
The study did not achieve statistical significance on the primary endpoint Tonix is discontinuing development of TNX-601 ER based on the efficacy results of this study Tonix expects topline data...
Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress
October 30, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is currently in Phase 1 Clinical Development Tonix is Developing TNX-1500 for...
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs
October 26, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline results expected early December 2023 Novel formulation of intranasal oxytocin contains magnesium (Mg2+), shown to potentiate the analgesic effects of oxytocin on the oxytocin receptor...